SDZ281-977

Research use only, not for human use.

SDZ 281-977 is a derivative of Lavendustin A, an EGF receptor tyrosine kinase inhibitor.

SDZ 281-977 is a derivative of the EGF receptor tyrosine kinase inhibitor Lavendustin A.

The anticancer profile of SDZ 281-977 is investigated in nude mice bearing the human tumor cell lines A431 (vulvar carcinoma cells), MIA PaCa-2 (pancreatic tumor cells) and MDA-MB-231 (breast carcinoma cells). These cell lines are selected because of their sensitivity for SDZ 281-977. The IC50 values for inhibition of growth of A431, MIA PaCa-2 and MDA-MB-231 cells are 0.21 μM, 0.29 μM and 0.43 μM, respectively.

Nude mice bearing A431 human vulvar carcinomas receive intravenous injections of SDZ 281-977 (1-10 mg/kg) for 4 weeks. This treatment results in a dose-dependent inhibition of tumor growth. Orally administered SDZ 281-977 (30 mg/kg) induces a 54% inhibition of A431 tumor growth after 3 weeks of treatment. The above regimens are well tolerated. No significant change in body weight occurred during treatment.

——

Angiogenesis

EGFR

EGFR

——

——

150779-71-8

316.35

C18H20O5

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (316.11 mM; Ultrasonic )

COC(=O)c1cc(CCc2cc(OC)ccc2OC)ccc1O

——

(-20℃)

With Ice Pack

≥ 2 years